Last reviewed · How we verify
Ajmalin (AJMALINE)
Ajmalin (generic name: AJMALINE) is a ajmaline drug. It is currently in Phase 3 development for Cardiac arrhythmia, Supraventricular arrhythmia, Ventricular arrhythmia.
Ajmaline works by blocking potassium channels in the heart to help regulate heart rhythm.
Ajmaline, a small molecule drug, targets the potassium voltage-gated channel subfamily A member 5 to treat cardiac arrhythmias, including supraventricular and ventricular arrhythmias. Its mechanism of action involves blocking potassium channels, which helps to regulate heart rhythm. The commercial status of ajmaline is unclear, and it may be patented or have generic manufacturers. Key safety considerations include its potential to cause cardiac side effects. Ajmaline has a half-life of 7.3 hours.
-
Baseline phase 3 → approval rate
+58.3pp
Industry-wide phase 3 drugs reach approval ~58.3% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas). -
Cardiovascular Phase 3 risk
-2.0pp
Modern cardiovascular outcome trials are large + long; many fail to beat aggressive standard-of-care.
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2028–2030 | — |
| EMA | EU | 2029–2031 | +0.7 yr |
| MHRA | GB | 2029–2031 | +0.7 yr |
| Health Canada | CA | 2029–2032 | +0.9 yr |
| TGA | AU | 2029–2032 | +1.2 yr |
| PMDA | JP | 2029–2032 | +1.5 yr |
| NMPA | CN | 2030–2033 | +2.3 yr |
| MFDS | KR | 2029–2032 | +1.4 yr |
| CDSCO | IN | 2029–2033 | +1.8 yr |
| ANVISA | BR | 2030–2033 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | AJMALINE |
|---|---|
| Drug class | ajmaline |
| Target | Potassium voltage-gated channel subfamily A member 5 |
| Modality | Small molecule |
| Therapeutic area | Cardiovascular |
| Phase | Phase 3 |
Mechanism of action
Think of your heart as a pump that beats in a regular rhythm. Potassium channels help control how fast the heart beats. Ajmaline blocks these channels, which helps to slow down the heart rate and restore a normal rhythm.
Approved indications
- Cardiac arrhythmia
- Supraventricular arrhythmia
- Ventricular arrhythmia
Common side effects
Key clinical trials
- Artificial Intelligence for the Prioritization of Genetic Background in Brugada Syndrome
- Feasibility of Improving Risk Stratification in Brugada Syndrome
- Defining the Electrocardiographic Effect of Propofol on the Ajmaline Provocation Drug Challenge: A Prospective Trial
- Right Ventricle Morphology and Hemodynamics in BrS
- The Response To Ajmaline Provocation in Healthy Subjects (PHASE2)
- AnalyST & Brugada Syndrome - Feasibility Study (NA)
- Echocardiography During Ajmaline Test
- Epicardial Ablation in Brugada Syndrome (NA)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Ajmalin CI brief — competitive landscape report
- Ajmalin updates RSS · CI watch RSS
Frequently asked questions about Ajmalin
What is Ajmalin?
How does Ajmalin work?
What is Ajmalin used for?
What is the generic name of Ajmalin?
What drug class is Ajmalin in?
What development phase is Ajmalin in?
What does Ajmalin target?
Related
- Drug class: All ajmaline drugs
- Target: All drugs targeting Potassium voltage-gated channel subfamily A member 5
- Therapeutic area: All drugs in Cardiovascular
- Indication: Drugs for Cardiac arrhythmia
- Indication: Drugs for Supraventricular arrhythmia
- Indication: Drugs for Ventricular arrhythmia
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing